2014 Rheumatology Highlights From Boston*

November 15-19, 2014; Boston, Massachusetts
Review highlights from the 2014 Boston rheumatology meeting in CCO’s Independent Conference Coverage, which includes clinical commentary, a Conference Report with embedded slides, and a downloadable slideset.
Vinod Chandran, MBBS, MD, DM, PhD
Chad Deal, MD
Atul Deodhar, MD
Daniel J. Wallace, MD

Rheumatoid Arthritis

Chad Deal, MD, explores the clinical significance of key studies in rheumatoid arthritis presented at the 2014 American College of Rheumatology Annual Meeting.

Chad Deal, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 5, 2015 Expiration: March 4, 2016

In this downloadable slideset, Chad Deal, MD, explores the clinical significance of key studies in rheumatoid arthritis presented at the 2014 American College of Rheumatology Annual Meeting.

Released: March 5, 2015

Lupus, Psoriatic Arthritis, and Spondyloarthritis

In these highlights from the ClinicalThought program, CCO’s expert faculty members describe how they tackle challenging clinical decisions in the settings of lupus, psoriatic arthritis, and spondyloarthritis.

Vinod Chandran, MBBS, MD, DM, PhD Atul Deodhar, MD Daniel J. Wallace, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: March 19, 2015 Expiration: March 18, 2016

Clinical Thoughts

Two phase II late-breaking plenary oral abstracts at ACR offered tantalizing suggestions that could inform a successful phase III effort. Other presentations of note focused on the importance of patient-reported outcomes and the intriguing potential of studying already approved drugs in SLE.

Daniel J. Wallace, MD Released: January 29, 2015

The 2014 American College of Rheumatology annual meeting provided us with new and promising data on the safety and efficacy of current and investigational agents. How soon will we have new treatment options for patients with PsA?

Vinod Chandran, MBBS, MD, DM, PhD Released: February 6, 2015

Research presented at the 2014 ACR annual meeting showed that targeting the IL-23/IL-17 axis in ankylosing spondylitis led to high ASAS20 responses, and the use of TNF inhibitors benefits patients with nonradiographic axial spondyloarthritis.

Atul Deodhar, MD Released: February 6, 2015
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?